Internet-delivered Cognitive Behavior Therapy for Atrial Fibrillation

Sponsor
Karolinska Institutet (Other)
Overall Status
Completed
CT.gov ID
NCT03378349
Collaborator
(none)
126
1
2
32.4
3.9

Study Details

Study Description

Brief Summary

The aim is to evaluate if internet- delivered cognitive behavior therapy (CBT), based on exposure principles and behavioral activation, improves QoL and symptom burden in patients with symptomatic atrial fibrillation (AF) compared to treatment as usual. The study will include 120 patients with symptomatic AF despite optimal medical treatment in accordance with current guidelines.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Internet-delivered cognitive behavior therapy
  • Behavioral: Treatment as usual
N/A

Detailed Description

Atrial fibrillation (AF) is the most common cardiac arrhythmia (irregular heartbeat) affecting 3% of the population. AF is associated with poor quality of life (QoL) and large costs for society. In a considerable proportion of patients, AF symptoms (e.g., palpitations, fatigue, and chest pain) are not alleviated by current medical or interventional treatments. Psychological factors can worsen AF symptoms, and anxiety and depression are common among AF patients. Symptom preoccupation and avoidance of social and physical activities are likely to play important roles in the development of anxiety, depression, disability and healthcare utilization.

The aim is to evaluate if CBT, based on behavioral activation and exposure principles, improves wellbeing and QoL in symptomatic AF patients more than a wait list offered treatment as usual.

Method: A randomized controlled trial. Participants are randomized to internet-delivered CBT for 10 weeks (N=60) or to treatment as usual (N=60). The internet-delivered CBT-program will last for 10 weeks and include weekly therapist support, consisting of online messages and telephone calls. Patients on the treatment as usual wait list will be provided standardized written information about basic self-management in AF. The treatment as usual wait list will be crossed over to treatment 3 months after the treatment group has completed treatment.

Study Design

Study Type:
Interventional
Actual Enrollment :
126 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Internet-delivered Cognitive Behavior Therapy for Atrial Fibrillation - a Randomized Controlled Trial
Actual Study Start Date :
Jan 8, 2018
Actual Primary Completion Date :
Dec 20, 2019
Actual Study Completion Date :
Sep 20, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Internet-delivered CBT over 10 weeks

The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.

Behavioral: Internet-delivered cognitive behavior therapy
The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.

Placebo Comparator: Treatment as usual wait list

Patients randomized to the treatment as usual wait list arm will receive standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health. Thus, the treatment as usual arm will control for the provision of basic patient information, but without the guidance of a psychologist or any CBT interventions.

Behavioral: Treatment as usual
Consist of standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health, without the guidance of a psychologist or any CBT interventions.

Outcome Measures

Primary Outcome Measures

  1. The Atrial Fibrillation Quality of Life (AFEQT) [From baseline to 6 months PRIMARY ENDPOINT]

    The AFEQT is an atrial fibrillation-specific measure that taps into the QoL-domains: symptoms, daily activities, treatment concern, and treatment satisfaction.

  2. The Atrial Fibrillation Quality of Life (AFEQT) [From baseline to 12 weeks]

    The AFEQT is an atrial fibrillation-specific measure that taps into the QoL-domains: symptoms, daily activities, treatment concern, and treatment satisfaction.

  3. The Atrial Fibrillation Quality of Life (AFEQT) [From baseline to 9 months]

    The AFEQT is an atrial fibrillation-specific measure that taps into the QoL-domains: symptoms, daily activities, treatment concern, and treatment satisfaction.

  4. The Atrial Fibrillation Quality of Life (AFEQT) [From baseline to 15 months]

    The AFEQT is an atrial fibrillation-specific measure that taps into the QoL-domains: symptoms, daily activities, treatment concern, and treatment satisfaction.

Secondary Outcome Measures

  1. Electrocardiography (ECG) measurement [From baseline to 12 weeks]

    Change in symptomatic burden. The patient will undergo 5 days ECG assessment in order to measure objectively symptomatic burden (number and duration of symptomatic AF episodes and symptomatic "non-AF episodes")

  2. ECG measurement [From baseline to 6 months]

    Change in symptomatic burden. The patient will undergo 5 days ECG assessment in order to measure objectively symptomatic burden (number and duration of symptomatic AF episodes and symptomatic "non-AF episodes")

  3. ECG measurement [From baseline to 15 months]

    Change in symptomatic burden. The patient will undergo 5 days ECG assessment in order to measure objectively symptomatic burden (number and duration of symptomatic AF episodes and symptomatic "non-AF episodes")

  4. Cardiac Anxiety Questionary (CAQ) [From baseline to 12 weeks]

    Symptom preoccupation

  5. Cardiac Anxiety Questionary (CAQ) [From baseline to 6 months]

    Symptom preoccupation

  6. Cardiac Anxiety Questionary (CAQ) [From baseline to 9 months]

    Symptom preoccupation

  7. Cardiac Anxiety Questionary (CAQ) [From baseline to 15 months]

    Symptom preoccupation

  8. the World Health Organization Disability Assessment Schedule (WHODAS 2.0, 12- item version) [From baseline to 12 weeks]

    General quality of life

  9. WHODAS 2.0 (12-item version) [From baseline to 6 months]

    General quality of life

  10. WHODAS 2.0 (12-item version) [From baseline to 15 months]

    General quality of life

  11. Symptom checklist Severity and Frequency Scale (SCL) [From baseline to 12 weeks]

    AF related symptoms

  12. Symptom checklist Severity and Frequency Scale (SCL) [From baseline to 6 months]

    AF related symptoms

  13. Symptom checklist Severity and Frequency Scale (SCL) [From baseline to 15 months]

    AF related symptoms

  14. Atrial Fibrillation Severity Scale [From baseline to 12 weeks]

    Symptomatic burden

  15. Atrial Fibrillation Severity Scale [From baseline to 6 months]

    Symptomatic burden

  16. Atrial Fibrillation Severity Scale [From baseline to 15 months]

    Symptomatic burden

  17. Patient Health Questionnaire (PHQ-9) [From baseline to 12 weeks]

    Depression

  18. PHQ-9 [From baseline to 6 months]

    Depression

  19. PHQ-9 [From baseline to 15 months]

    Depression

  20. Client satisfaction Questionnaire [From baseline to 12 weeks]

    Treatment satisfaction

  21. Adverse events [From baseline to 12 weeks]

    Potential adverse reactions to the treatment

Other Outcome Measures

  1. Self-rated health, 1 item [From baseline to 12 weeks]

    The measure consists of a single item that asks the participants to rate their overall health as excellent, good, fair, or poor.

  2. Self-rated health, 1 item [From baseline to 6 months]

    The measure consists of a single item that asks the participants to rate their overall health as excellent, good, fair, or poor.

  3. Self-rated health, 1 item [From baseline to 15 months]

    The measure consists of a single item that asks the participants to rate their overall health as excellent, good, fair, or poor.

  4. Healthcare consumption and work loss:Tic-P [From baseline to 12 weeks]

    The Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry assesses societal cost during the last month. These costs include the participant's health care consumption (direct medical costs), time spent in other health promoting activities (direct non-medical costs), and sick leave, unemployment, and reduced work capacity at work and in the domestic realm (indirect non-medical costs).

  5. Healthcare consumption and work loss:Tic-P [From baseline to 6 months]

    The Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry assesses societal cost during the last month. These costs include the participant's health care consumption (direct medical costs), time spent in other health promoting activities (direct non-medical costs), and sick leave, unemployment, and reduced work capacity at work and in the domestic realm (indirect non-medical costs).

  6. Healthcare consumption and work loss:Tic-P [From baseline to 15 months]

    The Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry assesses societal cost during the last month. These costs include the participant's health care consumption (direct medical costs), time spent in other health promoting activities (direct non-medical costs), and sick leave, unemployment, and reduced work capacity at work and in the domestic realm (indirect non-medical costs).

  7. The International Physical Activity Questionnaire [From baseline to 6 months]

    Physical activity

  8. The International Physical Activity Questionnaire [From baseline to 12 weeks]

    Physical activity

  9. The International Physical Activity Questionnaire [From baseline to 9 months]

    Physical activity

  10. The International Physical Activity Questionnaire [From baseline to 15 months]

    Physical activity

  11. Body Sensation Questionnaire [From baseline to 12 weeks]

    Fear of bodily sensations

  12. Body Sensation Questionnaire [From baseline to 6 months]

    Fear of bodily sensations

  13. Body Sensation Questionnaire [From baseline to 15 months]

    Fear of bodily sensations

  14. Anxiety Sensitivity Index [From baseline to 12 weeks]

    Anxiety sensitivity

  15. Anxiety Sensitivity Index [From baseline to 6 months]

    Anxiety sensitivity

  16. Anxiety Sensitivity Index [From baseline to 15 months]

    Anxiety sensitivity

  17. Accelerometer [From baseline to 12 weeks]

    Objective measurement of physical activity 1 week

  18. Accelerometer [From baseline to 6 months]

    Objective measurement of physical activity 1 week

  19. Accelerometer [From baseline to 15 months]

    Objective measurement of physical activity 1 week

  20. Perceived stress scale (4-item version) [From baseline to 12 weeks]

    Stress reactivity

  21. Perceived stress scale (4-item version) [From baseline to 6 months]

    Stress reactivity

  22. Perceived stress scale (4-item version) [From baseline to 9 months]

    Stress reactivity

  23. Perceived stress scale (4-item version) [From baseline to 15 months]

    Stress reactivity

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Inclusion criteria: A) Paroxysmal AF ≥ once per month that causes moderate to severe symptoms and leads to significant distress or interferes with daily life (i.e. EHRA class ≥ IIb) ; B) Age 18-75 years; C) On optimal medical treatment; D). Able to read and write in Swedish.
Exclusion Criteria:
  • (E) heart failure with severe systolic dysfunction (ejection fraction ≤ 35%); (F) significant valvular disease; (G) planned ablation for AF or ablation within 3 months before assessment; (H) other severe medical illness; (I) any medical restriction to physical exercise; (J) severe psychiatric disorder, severe depression, or risk of suicide; (K) alcohol dependency.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Karolinska universitetssjukhuset Solna Stockholm Sweden

Sponsors and Collaborators

  • Karolinska Institutet

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Brjann Ljotsson, Associate professor, PhD, Lic. psychologist, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT03378349
Other Study ID Numbers:
  • AF RCT 1
First Posted:
Dec 19, 2017
Last Update Posted:
Sep 23, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 23, 2020